Weather forecast
Partly cloudy
Hold
Score 48/100 · Confidence 55%
A mixed forecast — patience tends to pay here.
Why this call
Strong recent buying pressure continues to be a major factor for the stock.
Declining revenue and a lack of profits create fundamental headwinds.
The 52-week high of $68 could act as a price ceiling.
Under the hood
Six factors, scored 0–100 from live market and financial data — the same read Wall Street does, minus the jargon.
The company's lack of profits makes it difficult to value with traditional metrics.
Revenue has declined significantly over the past year as vaccine sales have slowed.
The company is currently unprofitable on a net basis, with deeply negative margins.
The stock has shown exceptionally strong price performance, trading near its 52-week high.
The balance sheet is very strong, with a low debt-to-equity ratio.
Market sentiment appears neutral in the absence of major recent news.
The argument
Every call has a case against it. Here's the honest version of both.
The bull case
The bear case
Get the full picture
You just understood MRNA without reading a single chart. The Tickerday app does this for your whole watchlist — the full thesis, price targets from next week to next year, bull and bear scenarios — and wakes you the moment the weather turns.
One plain answer for every stock — Buy, Hold, or Sell
The full picture in seconds — thesis, targets & scenarios
Sleep easy — we watch the market and wake you if it turns
Free to download · 7-day free Tickerday+ trial inside